🔎 Trials Near Me

Akèy › Kasinòm epitelyal ovè › Massachusetts

Etid klinik pou Kasinòm epitelyal ovè nan Massachusetts

9 etid pou Kasinòm epitelyal ovè ap chèche patisipan nan sit nan Massachusetts.

Vil nan Massachusetts

Tèks ofisyèl etid la (Anglè)

A Study of Isoquercetin in People With Ovarian Cancer

  • Beth Israel Deaconess Medical Center (Data Collection Only), Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT07303894

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

  • Research Site, Burlington
  • Research Site, Worcester
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Jul 21, 2026 · NCT07218809

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Jul 2, 2026 · NCT06819007

A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

  • Site 0104, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Fanm · Mizajou Apr 7, 2026 · NCT04516447

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

  • Massachusetts General Hospital, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Mar 27, 2026 · NCT06395519

A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

  • Massachusetts General Hospital, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Fanm · Mizajou Feb 3, 2026 · NCT06469281

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

  • Massachusetts General Hospital, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Dec 23, 2025 · NCT06690775

Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer

  • Massachusetts General Hospital, Boston
Ap rekriteEtid obsèvasyon
Laj 30 ak plis · Fanm · Mizajou Sep 16, 2025 · NCT04794322

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

  • Dana Farber/Partners Cancer Care Inc, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 15, 2025 · NCT04429542

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.